Looking for a Treatment for the Early Stage of Alzheimer's Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin
Laboratory studyOther animalsWith luteolin (co-ultramicronised PEA/luteolin, PEALut)
This study tested palmitoylethanolamide together with luteolin (co-ultramicronised PEA/luteolin, PEALut). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Rats given a single hippocampal infusion of amyloid-beta (1-42), 5 micrograms, to model prodromal Alzheimer's disease
- Dose used in the study
- Co-ultramicronised PEALut, 5 mg/kg, administered for 14 days
- Duration
- 14 days
- What was measured
- Glial activation (astrogliosis, microgliosis), pro-inflammatory cytokine and enzyme gene expression, and BDNF/GDNF mRNA levels after amyloid-beta infusion
What the authors reported
This laboratory study found:
- Amyloid-beta infusion raised glial activation and pro-inflammatory mediators.
- Early PEALut treatment prevented the amyloid-beta-induced astrogliosis and microgliosis.
- PEALut treatment prevented the rise in pro-inflammatory cytokine and enzyme gene expression, and prevented the reduction in BDNF and GDNF mRNA.
- PEALut also promoted neuronal survival.
Limits of this study
A rat model of induced amyloid-beta pathology; it cannot show effect in people. Funded by a Sapienza University of Rome grant; no other conflicts stated.
Source
PubMed 32471239 · doi:10.3390/ijms21113802
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.